Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

Bempegaldesleukin (BEMPEG), a CD122-preferential IL2 pathway agonist, has been shown to induce proliferation and activation of NK cells. NK activation is dependent on the balance of inhibitory and excitatory signals transmitted by NK receptors, including Fc-gamma receptors (FCγRs) and killer immunog...

Descripción completa

Detalles Bibliográficos
Autores principales: Feils, A. S., Erbe, A. K., Birstler, J., Kim, K., Hoch, U., Currie, S. L., Nguyen, T., Yu, D., Siefker-Radtke, A. O., Tannir, N., Tolaney, S. M., Diab, A., Sondel, P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264535/
https://www.ncbi.nlm.nih.gov/pubmed/36823323
http://dx.doi.org/10.1007/s00262-023-03383-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264535/
https://www.ncbi.nlm.nih.gov/pubmed/36823323
http://dx.doi.org/10.1007/s00262-023-03383-w

Ejemplares similares